Antipsychotic Drugs in Autistic Children using LC/MS-MS: Better-Fixed Doses Necessary for the Middle East

Abstract

This study aims to investigate the effectiveness of drug doses prescribed to autistic children in the Middle East. The uniqueness of this study relies on the fact that fewer research profiles in this study area are available in the Middle East. Specifically, this study presents recommendations based on accurate measurements in plasma compared to the prescribed doses. Plasma samples from 18 children were collected. Levels of olanzapine, risperidone, and quetiapine drugs were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This is a powerful accurate analytical tool in which the coefficient of determination (R 2 ) was greater than 0.998. The coefficient of variation and relative error was less than 15%. Steady-state concentrations for the previously mentioned drugs were less than the determined concentration in plasma. A better-effective treatment for people affected by autism spectrum disorder (ASD) is needed to reduce/eliminate the side effects as well as increase the effectiveness to achieve the best outcome. For improvement functions, better fixed doses of the medications were necessary for better performance. In addition, increasing awareness of the importance of finding a better-effective treatment for people affected by autism spectrum disorder (ASD) is essential. This will optimize the activation/inhibition of some enzymes. More effective treatment guidelines must be developed for patients with ASD. Keywords: autism spectrum disorder, olanzapine, risperidone, quetiapine, children’s health, drug dose, liquid chromatography-tandem mass spectrometry. https://doi.org/10.55463/issn.1674-2974.50.4.17